Viridian Therapeutics, Inc. · NASDAQ:VRDN
Paradigm Biocapital Advisors LP reported a 6.10% stake in Viridian Therapeutics, Inc. (Schedule 13G/A)
Event Jun 30, 2026 · Filed Aug 14, 2026
Paradigm Biocapital Advisors LP reported a 6.10% stake in Viridian Therapeutics, Inc., 6,723,788 shares, as a passive investor on Jun 30, 2026. Filed Aug 14, 2026 (Schedule 13G/A).
- Stake
- 6.10%
- Shares
- 6,723,788
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 4 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Paradigm BioCapital Advisors LP | 6.10% | 6,723,788 |
| Paradigm BioCapital Advisors GP LLC | 6.10% | 6,723,788 |
| Senai Asefaw, M.D. | 6.10% | 6,723,788 |
| Paradigm BioCapital International Fund Ltd. | 5.30% | 5,896,154 |
Source
Related
- Viridian Therapeutics, Inc.
- Paradigm Biocapital Advisors LP
- Viridian Therapeutics, Inc. shareholders
- Schedule 13G · Paradigm Biocapital Advisors LP · Jun 26, 2026
- Form 4 · Tousignant Jennifer · Aug 20, 2026
- Schedule 13G · Point72 Asset Management, L.P. · Aug 20, 2026
- Form 4 · Tripuraneni Radhika · Aug 18, 2026
- Schedule 13G · T. Rowe Price Associates Inc · Aug 14, 2026
- Schedule 13G/A · Deep Track Capital, LP · Aug 14, 2026